July 24, 2023 – The U.S. FDA announced the approval of quizartinib, an important new therapy for patients with leukemia. This global effort to impact patients in need is to be celebrated while recognizing the contributions from across the Canadian health R&D ecosystem to reach this significant milestone that will now make a difference for patients.